statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Investors Have the Opportunity to Join the Following Securities Fraud Investigations: Avangrid, Inc. (AGR), Squarespace, Inc. (SQSP), and Blueprint Medicines Corporation (BPMC)

Investors Have the Opportunity to Join the Following Securities Fraud Investigations: Avangrid, Inc. (AGR), Squarespace, Inc. (SQSP), and Blueprint Medicines Corporation (BPMC) Investors Have the...

Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024

Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR...

Expert Ratings For Blueprint Medicines

Latest Ratings for BPMC
 DateFirmActionFromTo Mar 2022StifelMaintainsBuy Mar 2022CitigroupInitiates Coverage OnNeutral Feb 2022SVB LeerinkDowngradesOutperformMarket Perform
 View More Analyst...

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT/AYVAKYT (avapritinib)

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT/AYVAKYT (avapritinib) Blueprint Medicines Announces Data...

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO...

Unveiling 18 Analyst Insights On Blueprint Medicines

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass...

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Volume	435,535.00
52-Wk High	$121.90
52-Wk Low	$43.89

BPMC Blueprint Medicines Corp

About

Feed

News

Sentiment

Earnings

Fundamentals